Cart
sales@molnova.com
Carrageenan
CAS No. 9000-07-1
Carrageenan( —— )
Catalog No. M16466 CAS No. 9000-07-1
A linear sulfated polysaccharide extracted from red edible seaweeds, shows topical microbicide activity targeting HIV viruses.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameCarrageenan
-
NoteResearch use only, not for human use.
-
Brief DescriptionA linear sulfated polysaccharide extracted from red edible seaweeds, shows topical microbicide activity targeting HIV viruses.
-
DescriptionA linear sulfated polysaccharide extracted from red edible seaweeds, shows topical microbicide activity targeting HIV viruses; carrageenan-based gels may prevent HIV transmission during sexual intercourse; also is a potent inhibitor of papillomavirus infection.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMicrobiology/Virology
-
TargetHIV
-
RecptorHIV
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number9000-07-1
-
Formula Weight——
-
Molecular Formula——
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?H2O : 3.33 mg/mL
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Neurath AR, et al. BMC Infect Dis. 2002 Nov 21;2:27.
2. Buck CB, et al. PLoS Pathog. 2006 Jul;2(7):e69.
3. Singer R, et al. J Virol. 2011 Jun;85(11):5504-12.
molnova catalog
related products
-
Bictegravir
Bictegravir (GS 9883) is a novel potent HIV-1 integrase (IN) that specifically targets IN strand transfer activity with IC50 of 7.5 nM.
-
MUT-A
MUT-A is a novel potent, HIV-1 Integrase IN-LEDGF allosteric inhibitor, shows potent anti-HIV activity with EC50 of 32 nM and 12 nM for NL4-3 or HxB2 HIV-1 strains, respectively.
-
KNI-1657
KNI-1657 (KNI1657) is a highly potent HIV-1 protease inhibitor (97% inhibition at 1 nM) with high sensitivity against lopinavir/ritonavir- or darunavir-resistant strains.
